Article

Farrant, JP, Schmitt, M, Reid, AB, Garratt, CJ, Newman, WG, Malhotra, A, Beynon, R, Mahmod, M, Raman, B, Cooper, RM, Dawson, D, Green, T, Prasad, SK, Singh, A, Dodd, S, Watkins, H, Neubauer, S and Miller, CA (2024) Considerations for drug trials in hypertrophic cardiomyopathy. ESC Heart Failure.

Farrant, J, Dodd, S, Vaughan, C, Reid, A, Schmitt, M, Garratt, C, Akhtar, M, Mahmod, M, Neubauer, S, Cooper, RM, Prasad, SK, Singh, A, Valkovič, L, Raman, B, Ashkir, Z, Clayton, D, Baroja, O, Duran, B, Spowart, C, Bedson, E et al, Naish, JH, Harrington, C, Miller, CA and TEMPEST investigators, (2023) Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy. Heart (British Cardiac Society). ISSN 1355-6037

Raphael, CE, Mitchell, F, Kanaganayagam, GS, Liew, AC, Di Pietro, E, Vieira, MS, Kanapeckaite, L, Newsome, S, Gregson, J, Owen, R, Hsu, LY, Vassiliou, V, Cooper, R, Mrcp, AA, Ismail, TF, Wong, B, Sun, K, Gatehouse, P, Firmin, D, Cook, S et al, Frenneaux, M, Arai, A, O’Hanlon, R, Pennell, DJ and Prasad, SK (2021) Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation. Journal of Cardiovascular Magnetic Resonance, 23 (1). ISSN 1097-6647